Create Medicines (formerly Myeloid Therapeutics) announced a strategic expansion beyond myeloid programming to include in vivo mRNA‑LNP programming of T cells and NK cells, aiming for scalable, redosable in‑body CAR therapeutics. CEO Daniel Getts outlined a plan to advance in vivo CARs targeting HER2, TROP2 and GPC3 and highlighted early signals of partial responses and tumor microenvironment modulation. Separately, Liberate Bio raised $31 million in seed funding from Khosla Ventures to develop an LNP platform for direct in vivo immune cell reprogramming. The capital will support preclinical validation and LNP formulation work to enable intravenous infusions that program immune cells inside patients. Both announcements signal acceleration in the in‑body cell‑therapy paradigm that seeks to remove complex ex‑vivo manufacturing bottlenecks. The field will monitor delivery specificity, repeat dosing tolerability, and translation of preclinical efficacy into human trials.